Esophageal carcinoma (squamous + adeno)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-ESOPHAGEAL |
|---|---|
| Type | Disease |
| Aliases | Esophageal SCC + adenocarcinomaEsophageal cancerEsophageal carcinomaКарцинома стравоходу (плоскоклітинна + аденокарцинома) |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8070/3 |
|---|---|
| icd_o_3_topography | ["C15"] |
| icd_10 | C15 |
| who_classification | WHO Digestive System Tumours 5th ed: Esophageal squamous cell carcinoma + esophageal adenocarcinoma |
Notes
Scaffolded for Phase GI-1: 1 RF (high-grade dysphagia / aspiration — most common acute presentation), 1 indication (CROSS-style scaffold noting RT not modellable), 1 algorithm. Full histology-stratified algorithm (squamous: definitive CRT for unresectable, CROSS for resectable; adeno: FLOT preferred for resectable, CROSS alternative) + adjuvant nivolumab post-CROSS without pCR + metastatic biomarker- stratified ICI/chemo combos await ratification + clinical authoring. Histology branching is critical — squamous and adeno have largely parallel but partially divergent paradigms. Per-prompt allowance: one disease YAML covers both, with histology field on Indication applicability.
Used By
Actionability
BMA-HER2-AMP-ESOPHAGEAL- HER2-positive esophageal/GEJ adenocarcinoma scored by gastric criteria: trastuzumab + che...BMA-PDL1-CPS-ESOPHAGEAL- PD-L1 CPS used as eligibility threshold for ICI in metastatic esophageal cancer. Esophage...BMA-PIK3CA-HOTSPOT-ESOPHAGEAL- PIK3CA mutations in ~10% of esophageal SCC/AC. No PI3Ki approval; CRT or chemo/ICI per us...BMA-TP53-MUT-ESOPHAGEAL- TP53 mutation in ESOPHAGEAL — common, adverse prognostic; not directly targeted. Per usua...
Algorithms
ALGO-ESOPH-2L- ALGO-ESOPH-2LALGO-ESOPH-DEFINITIVE-1L- ALGO-ESOPH-DEFINITIVE-1LALGO-ESOPH-METASTATIC-1L- ALGO-ESOPH-METASTATIC-1LALGO-ESOPH-RESECTABLE-1L- ALGO-ESOPH-RESECTABLE-1LALGO-ESOPHAGEAL-ADJUVANT-1L- ALGO-ESOPHAGEAL-ADJUVANT-1L
Disease
DIS-GASTRIC- Gastric / GEJ adenocarcinomaDIS-LARYNGEAL- Laryngeal squamous cell carcinoma
Indication
IND-ACHALASIA-ESOPHAGEAL-PREVENTION-OBSERVATION- IND-ACHALASIA-ESOPHAGEAL-PREVENTION-OBSERVATIONIND-ACHALASIA-ESOPHAGEAL-PREVENTION-SURVEILLANCE- IND-ACHALASIA-ESOPHAGEAL-PREVENTION-SURVEILLANCEIND-BARRETTS-ESOPHAGUS-PREVENTION-OBSERVATION- IND-BARRETTS-ESOPHAGUS-PREVENTION-OBSERVATIONIND-BARRETTS-ESOPHAGUS-PREVENTION-SURVEILLANCE- IND-BARRETTS-ESOPHAGUS-PREVENTION-SURVEILLANCEIND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSS- IND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSSIND-ESOPH-DEFINITIVE-CRT-SCC- IND-ESOPH-DEFINITIVE-CRT-SCCIND-ESOPH-METASTATIC-1L-HER2-TRASTUZUMAB-CHEMO- IND-ESOPH-METASTATIC-1L-HER2-TRASTUZUMAB-CHEMOIND-ESOPH-METASTATIC-1L-NIVO-CHEMO-SCC- IND-ESOPH-METASTATIC-1L-NIVO-CHEMO-SCCIND-ESOPH-METASTATIC-1L-PEMBRO-CHEMO- IND-ESOPH-METASTATIC-1L-PEMBRO-CHEMOIND-ESOPH-METASTATIC-1L-SCC-IPI-NIVO- IND-ESOPH-METASTATIC-1L-SCC-IPI-NIVOIND-ESOPH-METASTATIC-2L-HER2-POSITIVE-T-DXD- IND-ESOPH-METASTATIC-2L-HER2-POSITIVE-T-DXDIND-ESOPH-METASTATIC-2L-NIVO-SQUAMOUS- IND-ESOPH-METASTATIC-2L-NIVO-SQUAMOUSIND-ESOPH-METASTATIC-2L-PEMBRO-CPS10- IND-ESOPH-METASTATIC-2L-PEMBRO-CPS10IND-ESOPH-OLIGOMET-SYSTEMIC-PLUS-LOCAL- IND-ESOPH-OLIGOMET-SYSTEMIC-PLUS-LOCALIND-ESOPH-RESECTABLE-CROSS-NEOADJUVANT- IND-ESOPH-RESECTABLE-CROSS-NEOADJUVANTIND-LIFESTYLE-HOT-BEVERAGES-PREVENTION-COOLING- IND-LIFESTYLE-HOT-BEVERAGES-PREVENTION-COOLINGIND-LIFESTYLE-HOT-BEVERAGES-PREVENTION-OBSERVATION- IND-LIFESTYLE-HOT-BEVERAGES-PREVENTION-OBSERVATIONIND-LIFESTYLE-HOT-MATE-ESOPHAGEAL-PREVENTION-INTENSIFIED-SURVEILLANCE- IND-LIFESTYLE-HOT-MATE-ESOPHAGEAL-PREVENTION-INTENSIFIED-SURVEILLANCEIND-LIFESTYLE-HOT-MATE-ESOPHAGEAL-PREVENTION-OBSERVATION- IND-LIFESTYLE-HOT-MATE-ESOPHAGEAL-PREVENTION-OBSERVATION
Procedures
SUR-ESOPHAGECTOMY-MIE- Minimally invasive esophagectomy (MIE)SUR-ESOPHAGECTOMY-OPEN- Open esophagectomy (Ivor-Lewis or McKeown)SUR-ESOPHAGECTOMY-RAMIE- Robot-assisted minimally invasive esophagectomy (RAMIE)
Questionnaires
QUEST-ESOPHAGEAL-1L-STUB- Esophageal carcinoma — first line
Red flag
RF-ACHALASIA-ESOPHAGEAL-PREVENTION- Achalasia (primary esophageal motor disorder with impaired LES relaxation and loss of eso...RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK- Patient with active or incompletely controlled pre-existing autoimmune or inflammatory di...RF-BARRETTS-ESOPHAGUS-PREVENTION- Barrett's esophagus (intestinal metaplasia of the distal esophagus with goblet cells on b...RF-ESOPH-FRAILTY-AGE- Frailty profile precluding CROSS / FLOT / definitive CRT in esophageal: ECOG ≥3, OR (age...RF-ESOPH-HIGH-RISK-BIOLOGY- Treatment-defining biomarkers in esophageal/EGJ cancer: HER2+ (adeno only — TOGA-style ga...RF-ESOPH-INFECTION-SCREENING- Infection-screening gate before esophageal cancer systemic therapy: HBsAg+ / anti-HBc+ (H...RF-ESOPH-SEVERE-DYSPHAGIA-ASPIRATION- Severe dysphagia with weight loss / aspiration risk in esophageal cancer: inability to sw...RF-ESOPH-TRANSFORMATION-PROGRESSION- Aggressive progression in esophageal cancer: residual disease post-CROSS (ypT+ or ypN+ at...RF-ESOPHAGEAL-POST-CROSS-NON-PCR- Post-CROSS-CRT-then-esophagectomy with residual disease — pathology shows ypT+ and/or ypN...RF-LIFESTYLE-ALCOHOL-CANCER-PREVENTION- Heavy alcohol consumption — defined as >14 drinks/week (women) or >21 drinks/week (men) p...RF-LIFESTYLE-HOT-BEVERAGES-PREVENTION- Regular consumption of very hot beverages (≥65°C / 149°F) per IARC Monograph 116 (2016) —...RF-LIFESTYLE-HOT-MATE-ESOPHAGEAL-PREVENTION- Regular consumption of maté (Ilex paraguariensis infusion) prepared and drunk at very hig...RF-LIFESTYLE-OBESITY-CANCER-PREVENTION- Obesity — BMI ≥30 kg/m² (per WHO definition) — OR class 2/3 obesity with BMI ≥35 / ≥40. I...RF-LIFESTYLE-SMOKELESS-TOBACCO-PREVENTION- Habitual use of smokeless tobacco products — chewing tobacco, snus (oral nicotine pouch w...RF-OLIGOMET-DEFINITION- Oligometastatic esophagogastric adenocarcinoma per OMEC-1 (OligoMetastatic Esophagogastri...
Sources
SRC-CHECKMATE-577-KELLY-2021- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerSRC-CHECKMATE-648-DOKI-2022- Nivolumab plus Chemotherapy or Ipilimumab in Esophageal Squamous-Cell CarcinomaSRC-CHECKMATE-649-JANJIGIAN-2022- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, ga...SRC-CROSS-VAN-HAGEN-2012- Preoperative chemoradiotherapy for esophageal or junctional cancerSRC-ESMO-ESOPHAGEAL-2024- ESMO Esophageal CancerSRC-ESMO-GASTRIC-2024- ESMO Gastric CancerSRC-FORTITUDE-101- Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing g...SRC-KEYNOTE-590-SUN-2021- Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Adv...SRC-NCCN-ESOPHAGEAL-2025- NCCN Esophageal and EGJ CancersSRC-OMEC-1-KROESE-2023- Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi...SRC-ROBOT-VAN-DER-SLUIS-2019- Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthor...SRC-RTOG-8501-HERSKOVIC-1992- Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with...SRC-TIME-BIERE-2012- Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a mul...